Midday Report: NanoViricides (NNVC) Shares Up on August 5

Equities Staff  |

Today NanoViricides Inc (NYSE: NNVC) is trading 39.55% up.

The latest price, as of 12:03:27 est, was $3.43. NanoViricides has risen $0.973 over the previous day’s close.

2,486,001 shares have exchanged hands.

As of the previous close, NanoViricides has a YTD change of 1.88%. The company is set to release earnings on 2022-09-28.

For technical charts, analysis, and more on NanoViricides visit the company profile.

About NanoViricides Inc

NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Its lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. In addition, it is developing a clinical candidate for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. The Company cannot project an exact date for filing an IND for this drug because of its dependence on a number of external collaborators and consultants.

To get more information on NanoViricides Inc and to follow the company's latest updates, you can visit the company's profile page here: NanoViricides Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Trending Articles

The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation

Market Movers

Sponsored Financial Content